Evidence map›Paper›PMID 36530157›Full record

Trial reportCancer2023

Reasons for refusal of the human papillomavirus vaccine among young cancer survivors.

Brooke Cherven, James L Klosky, K Elizabeth Keith, Melissa M Hudson, Smita Bhatia, Wendy Landier

Abstract readClinical Trial
In one paragraph

Trial report in Cancer, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Brooke ChervenDepartment of Pediatrics, Emory University School of Medicine, Atlanta, Georgia, USA.ORCID 0000-0002-5978-655X
James L KloskyDepartment of Pediatrics, Emory University School of Medicine, Atlanta, Georgia, USA.
K Elizabeth KeithInstitute for Cancer Outcomes and Survivorship, Department of Pediatrics, University of Alabama at Birmingham, Birmingham, Alabama, USA.
Melissa M HudsonDepartment of Epidemiology and Cancer Control, St. Jude Children's Research Hospital, Memphis, Tennessee, USA.
Smita BhatiaInstitute for Cancer Outcomes and Survivorship, Department of Pediatrics, University of Alabama at Birmingham, Birmingham, Alabama, USA.ORCID 0000-0002-7755-5683
Wendy LandierInstitute for Cancer Outcomes and Survivorship, Department of Pediatrics, University of Alabama at Birmingham, Birmingham, Alabama, USA.

Funding

Quadrivalent Human Papillomavirus (HPV) Vaccine in Cancer SurvivorsR01CA166559 · NCI · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI KLOSKY, JAMES, LANDIER, WENDY · 2012 to 2016
$3.0M
NCI NIH HHS R01 CA166559NCI NIH HHS R01CA166559
6 · The paper itself

Abstract

backgroundCancer survivors are at risk for developing subsequent human papillomavirus (HPV)-related malignancies. HPV vaccination rates among survivors remain low, and the reasons for refusal of the vaccine are unclear in this population.

methodsThe authors conducted a secondary analysis of data from an open-label clinical trial evaluating the immunogenicity and safety of the HPV vaccine among vaccine-naive cancer survivors who were 9-26 years old and 1-5 years from the completion of their cancer treatment. Survivors/parents who declined trial participation were asked their reasons for declining. Refusal reasons were categorized, and multivariable logistic regression models were developed to identify associations between survivor characteristics and primary refusal reasons.

resultsAmong the 301 survivors who refused participation in the clinical trial, 215 (71.4%) refused for reasons related to the HPV vaccine. Reasons for vaccine-related refusal included safety concerns, vaccine hesitancy/disinterest, external influences, vaccine-related information deficits, and health beliefs/family decisional processes. Compared with males, females were more likely to refuse for reasons related to health beliefs/family decisional processes (odds ratio [OR], 2.08; 95% confidence interval [CI], 1.12-3.93; p = .022) and were less likely to do so because of external influences (OR, 0.43; 95% CI, 0.19-0.92; p = .035). Survivors approached about participation during the latter years of the trial were more likely to refuse because of safety concerns (OR, 3.33; 95% CI, 1.55-7.69; p = .003).

conclusionsCancer survivors refused participation in an open-label trial evaluating the immunogenicity and safety of the HPV vaccine primarily because of vaccine-related concerns that were unrelated to the research study. Many of these concerns are potentially addressable by health care providers using evidence-based messages tailored to the cancer survivor population.

Indexed as

Cancer SurvivorsCancer VaccinesNeoplasmsPapillomavirus InfectionsPapillomavirus VaccinesAdolescentAdultChildFemaleHealth Knowledge, Attitudes, PracticeHuman Papillomavirus VirusesHumansMaleParentsVaccinationYoung AdultCancer VaccinesPapillomavirus Vaccinesadolescentcancer survivorshuman papillomavirus (HPV) vaccinationpediatricvaccine hesitancyyoung adult

Identifiers

PMID36530157
PMCPMC10283160

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.